VALIDATION EXPERIMENT Sample Clauses

VALIDATION EXPERIMENT. PERSONALIZED MEDIA MOBILITY IN URBAN ENVIRONMENTS 19 5 VALIDATION EXPERIMENT: COLLABORATIVE INTERACTIVE TRANSMEDIA NARRATIVES 33
AutoNDA by SimpleDocs
VALIDATION EXPERIMENT. AUGMENTED REALITY LOCATION-BASED GAMING 35 7 CONCLUSION 43 LIST OF FIGURES FIGURE 1. THE JOURNALIST AS A DESIGNER. CREATING TANGIBLE CONVERSATION OPENERS USED IN INTERVIEWS (PHOTO FLAME , 2018 ). 14 FIGURE 2. LOCAL NEWS ROOM ACTIVITIES. INCOMING INTERVIEW (PHOTO XXXX XXXXX, VRT INNOVATION, 2018) 14 FIGURE 3. STUDENTS EXPLORE THE INTERACTIVE MEDIA TRAIL WITH BRISTOL’S SUSTAINABLE FUTURE PLANS AND UNSDG AS THEMES (PHOTO XXXX XXXXX, VRT INNOVATION, 2019). 14 FIGURE 5. SERVICE FUNCTION CHAIN USED DURING THE SECOND EXPERIMENT. THE BACKEND FUNCTIONED AS A CONTROLLER SERVICE FOR THE WEB APPLICATION ON THE CLIENT. UPLOADED VIDEOS WERE TRANSCODED IN CHUNKS TO BE SERVED FOR THE ADAPTIVE STREAMING SERVICE. FIGURE 7. SCREENSHOTS OF THE VR APP. WE SEE THE CORRESPONDING TOPIC ‘ENVIRONMENT’ (SCREENSHOT XXXXX XXXXX, VRT INNOVATION, 2019) 15 FIGURE 9: PMM SCENARIO 1 -DISTRIBUTION OF PERSONAL MEDIA IN WALKING AREAS IN BARCELONA 20 FIGURE 10: PMM SCENARIO 2 - PMM FOR MULTIPLE CONCURRENT STREAMS WITHIN THE SMART CITY 20 FIGURE 11: PMM TRIAL BARCELONA – INITIAL DEPLOYMENT 21 FIGURE 12:PMM TRIAL BARCELONA – SCALE-OUT TRIGGER CONDITION 21 FIGURE 13: PMM TRIAL BARCELONA – SCALE-OUT CONFIGURATION 22 FIGURE 14. PMM TRIAL BARCELONA - MAP AND CHECKPOINTS 23 FIGURE 15: DRY RUN PHASE 1 (NO SCALE OUT FUNCTION) 24 FIGURE 16: DRY RUN PHASE 2 (SCALE OUT FUNCTION ACTIVATED) 25 FIGURE 17: PUBLIC TRIAL ACTIVE STREAMS OVER GATEWORKS 25 FIGURE 18: PMM TRIAL BARCELONA – VALID FRAMES OVER TOTAL NUMBER 29 FIGURE 19: PERCENTAGES OF CORRUPTED FRAMES 29 FIGURE 20: FRAMES DIVIDED PER DISTORTION DEGREES 30 FIGURE 21: BLOCKNESS FRAMES, MAX, AVERAGE AND MIN VALUES 30 FIGURE 22: AR GNOME SHOP (LEFT). AR GARDEN (MIDDLE). DIFFERENT TREE MODELS IN AR GARDEN (RIGHT) 36 FIGURE 23: THE SPIKE SHORTLY AFTER THE 8:38 MINUTES XXXX IS DUE TO A NEW PLAYER JOINING 37 FIGURE 25: THE TOTAL NUMBER OF REQUESTS SENT TO THE STORAGE FMS OVER THE TIME OF A GAME FOR DIFFERENT NUMBER OF PLAYERS 39 FIGURE 26: THE NETWORK USAGE TIME OF THE STORAGE FMS OVER THE TIME OF A GAME FOR DIFFERENT NUMBER OF PLAYERS 40 ABBREVIATIONS
VALIDATION EXPERIMENT. Once the hardware in-the-loop simulations are successful the final iteration is full runtime validation of the system without simulated components, i.e. in real conditions. This includes the human diver with disturbances like breathing, unpredicted variations from the path, non-zero roll and pitch, etc. Fig 5.4.4.1 shows results of diver following during the same transect as in hardware in-the-loop simulations. The mean tracking error across validation experiments is calculated to be about 1.8m. (b) Figure 5.4.4.1 Experimental results obtained from the validation experiment

Related to VALIDATION EXPERIMENT

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • Development Work The Support Standards do not include development work either (i) on software not licensed from CentralSquare or (ii) development work for enhancements or features that are outside the documented functionality of the Solutions, except such work as may be specifically purchased and outlined in Exhibit 1. CentralSquare retains all Intellectual Property Rights in development work performed and Customer may request consulting and development work from CentralSquare as a separate billable service.

  • Validation To validate the notice requirements outlined in Section 5.3, the Assuming Institution shall provide the Receiver (i) an Affidavit of Publication to meet the publication requirements outlined in Section 5.3(a) and (ii) the Assuming Institution will prepare an Affidavit of Mailing in a form substantially similar to Exhibit 2.3B after mailing the seven (7) day Notice to Depositors as required under Section 5.3(b).

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in xxxxx, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

  • DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK

  • Office of Inspector General Investigative Findings Expert Review In accordance with Senate Bill 799, Acts 2021, 87th Leg., R.S., if Texas Government Code, Section 531.102(m-1)(2) is applicable to this Contract, Contractor affirms that it possesses the necessary occupational licenses and experience.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!